文献速递哮喘

欧洲重症哮喘与缓解前景(SHARP):基于欧洲重症哮喘登记的多中心观察性研究

Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry.
PubMed 文献 · Lancet Respir Med · 2026-06-24

结果显示 despite 79%接受生物制剂治疗,89%患者至少有一个活动性疾病域,66%以上至少有两个活动域,2型生物标志物升高持续存在,提示当前治疗下缓解策略可能不足。

要点

  • 79%患者接受生物制剂治疗,但89%仍有至少一个活动性疾病域。
  • 66%以上患者 despite 生物制剂治疗仍至少有两个活动域。
  • 35%未使用生物制剂患者在不足10年内快速累积疾病负担。

核心结论

  • 欧洲重症哮喘患者 despite 先进治疗仍存在显著临床异质性和巨大疾病负担。
  • 2型炎症持续存在,当前可用治疗下缓解策略可能不足,需早期识别高危患者。

主要发现

  • despite 生物制剂治疗,66%以上(2621/3968)患者仍至少有两个活动域。
  • 89%(2806/3153)患者至少有一种2型生物标志物升高;35%(1069/3018)未使用生物制剂患者在不足10年内快速累积疾病负担。

临床怎么用

  • 临床应关注重症哮喘患者 despite 生物制剂治疗仍存在的多活动域负担,评估缓解可能性。
  • 对未使用生物制剂患者,需警惕不足10年内快速累积疾病负担的高危轨迹。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe asthma affects a minority of patients with asthma; however, it substantially impacts morbidity, health-care use, and systemic corticosteroid-related harm. Despite the increasing use of biological treatments, achievement of severe asthma remission remains elusive. Notably, real-world data on the disease burden and remission potential of severe asthma in Europe remain limited. We aimed to close this knowledge gap, offering insights with global relevance. METHODS: Using data from 13 455 adults with severe asthma enrolled in the European Severe Heterogeneous Asthma Registry, Patient-centred Clinical Research Collaboration (SHARP CRC), this cross-sectional observational study evaluated the burden of severe asthma and remission-related clinical domains (exacerbations, asthma control, airflow limitation, and maintenance oral corticosteroid use) across Europe and examined their relationship with disease duration, biological therapy, and type 2 biomarkers (blood eosinophils, fractional exhaled nitric oxide [FeNO], and total IgE). Patients with severe asthma had been enrolled in national registries according to local principles and guidelines and in accordance with the European Respiratory Society/American Thoracic Society guidelines; 3% (430 of 13 885) of patients were excluded due to no consent for the international study and/or missing medication data. FINDINGS: Patients were predominantly female (59%; 7999 of 13 453), with adult-onset asthma (82%; 8751 of 10 711), and a median disease duration of 23 years (95% CI 20-26 years). 59% (4148 of 7006) of patients had FEV1/FVC of 0·7 or less, 62% (4680 of 7568) had FEV1 lower than 80% predicted, and 89% (3519 of 3968) had at least one active disease domain. Despite 79% (10 632 of 13 453) receiving biological therapy, more than 66% (2621 of 3968) still had at least two active domains. Elevation of type 2 biomarkers persisted (89% [2806 of 3153] with at least one elevated biomarker) despite widespread biological and maintenance oral corticosteroid treatment. A subset of biologic-naive patients (35%; 1069 of 3018) exhibited a rapid accumulation of disease burden within less than 10 years, suggesting a potentially accelerated progression trajectory. INTERPRETATION: This pan-European analysis of severe asthma revealed significant clinical heterogeneity and a substantial disease burden despite advanced therapies, highlighting the enduring nature of type 2 inflammation, the potential inadequacy of current remission strategies with available therapeutic approaches, and the necessity for early identification of high-risk patients. FUNDING: SHARP Clinical Research Collaboration and consortium partners: European Respiratory Society, GlaxoSmithKline Research and Development, Chiesi Farmaceutici Società per Azioni, Novartis Pharma Aktiengesellschaft, Sanofi-Genzyme Corporation, and Teva Branded Pharmaceutical Products R&D.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Fouka E, Bansal AT, Håkansson KEJ, et al. Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry. Lancet Respir Med. 2026. PMID: 42341792. doi:10.1016/S2213-2600(26)00141-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。